Midodrine for the Early Liberation of Vasopressor Support in the ICU

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, they ask that the dose be adjusted to achieve a specific blood pressure. This kind of medical support with intravenous (IV) vasopressors are usual treatments in intensive care unit (ICU) settings. Oral vasopressors, such as midodrine, have been historically used to maintain blood pressure in non-critically ill patients. In this study, the investigators will be using midodrine to reduce the need for IV vasopressors as blood pressure improves during the stay in the ICU

The LIBERATE pilot study will evaluate the role of midodrine for patients with low blood pressure in the ICU. The investigators are planning on enrolling up to 60 study participants to evaluate this question in the General Systems ICU at the University of Alberta Hospital.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Collaborators: Alberta Health Services; Institute of Health Economics, Canada
• Treatments: Carboxymethylcellulose Sodium; Midodrine

Criteria

Inclusion Criteria:

• Age > 18 years old

• ICU admission

• Ongoing vasopressor support

• Decreasing vasopressor dose

Exclusion Criteria:

• Greater than 24 hours from peak vasopressor dose

• Contraindication to enteral medications

• Previously on midodrine in last 7 days

• Expected death or withdrawal of life-sustaining therapies

• Pregnancy

• Known allergy to Midodrine